AstraZeneca beats sales and profit expectations on cancer drug demand
Core earnings for the three months ended March rise to US$2.58 per share, while total revenue jumps 8% to US$15.3 billion
Add BT as a preferred source
[LONDON] AstraZeneca surpassed first-quarter sales and profit expectations, and maintained its 2026 outlook on Wednesday (Apr 29).
This comes as demand for its cancer drugs and investments in key markets helped the drugmaker navigate a complex geopolitical landscape.
Long-time CEO Pascal Soriot, 66, is steering the European drugmaking giant towards its goal of US$80 billion in annual sales by 2030, expanding AstraZeneca’s US and China footprint while manoeuvring geopolitics and shifting dynamics in the industry.
The company’s core earnings for the three months ended March rose to US$2.58 per share, while its total revenue jumped 8 per cent to US$15.3 billion at constant currency rates.
Analysts on average were expecting profit of US$2.54 per share on sales of US$14.9 billion, based on a company-compiled consensus.
AstraZeneca continued to expect core earnings per share this year to increase by a low double-digit percentage at constant currencies, with total revenues rising at a mid-to-high single-digit rate. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Malaysia’s 8th richest man Jeffrey Cheah wants Sunway business to last 10 generations
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
Banyan Group heir Ho Ren Yung: ‘Better to be useful than happy’
